PMID- 38126030
OWN - NLM
STAT- MEDLINE
DCOM- 20231222
LR  - 20231222
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Print)
IS  - 2162-4011 (Linking)
VI  - 12
IP  - 1
DP  - 2023
TI  - Identification and characterization of the anti-viral interferon lambda 3 as 
      direct target of the Epstein-Barr virus microRNA-BART7-3p.
PG  - 2284483
LID - 10.1080/2162402X.2023.2284483 [doi]
LID - 2284483
AB  - The human Epstein-Barr virus (EBV), as a member of the human gamma herpes viruses 
      (HHV), is known to be linked with distinct tumor types. It is a double-stranded 
      DNA virus and its genome encodes among others for 48 different microRNAs (miRs). 
      Current research demonstrated a strong involvement of certain EBV-miRs in 
      molecular immune evasion mechanisms of infected cells by, e.g., the disruption of 
      human leukocyte antigen (HLA) class Ia and NKG2D functions. To determine novel 
      targets of EBV-miRs involved in immune surveillance, ebv-miR-BART7-3p, an 
      EBV-encoded miR with high expression levels during the different lytic and latent 
      EBV life cycle phases, was overexpressed in human HEK293T cells. Using a cDNA 
      microarray-based comparative analysis, 234 (229 downregulated and 5 upregulated) 
      deregulated human transcripts were identified in ebv-miR-BART7-3p transfectants, 
      which were mainly involved in cellular processes and molecular binding. A 
      statistically significant downregulation of the anti-proliferative and 
      tumor-suppressive hsa-miR-34A and the anti-viral interferon lambda (IFNL)3 mRNA 
      was found. The ebv-miR-BART7-3p-mediated downregulation of IFNL3 expression was 
      due to a direct interaction with the IFNL3 3'-untranslated region (UTR) as 
      determined by luciferase reporter gene assays including the identification of the 
      accurate ebv-miR-BART7-3p binding site. The effect of ebv-miR-BART7-3p on the 
      IFNL3 expression was validated both in human cell lines in vitro and in human 
      tissue specimen with known EBV status. These results expand the current knowledge 
      of EBV-encoded miRs and their role in immune evasion, pathogenesis and malignant 
      transformation.
CI  - (c) 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
FAU - Blumke, Juliane
AU  - Blumke J
AD  - Institute for Medical Immunology, Martin-Luther-University Halle-Wittenberg, 
      Halle, Germany.
FAU - Bauer, Marcus
AU  - Bauer M
AD  - Institute for Pathology, Martin-Luther-University Halle-Wittenberg, Halle, 
      Germany.
FAU - Vaxevanis, Christoforos
AU  - Vaxevanis C
AD  - Institute for Medical Immunology, Martin-Luther-University Halle-Wittenberg, 
      Halle, Germany.
FAU - Wilfer, Andreas
AU  - Wilfer A
AD  - Institute for Pathology, Martin-Luther-University Halle-Wittenberg, Halle, 
      Germany.
AD  - Krukenberg Cancer Center, University Hospital Halle, Martin-Luther-University 
      Halle-Wittenberg, Halle, Germany.
FAU - Mandelboim, Ofer
AU  - Mandelboim O
AD  - Department of Immunology, Faculty of Medicine, The Hebrew University of 
      Jerusalem, Jerusalem, Israel.
FAU - Wickenhauser, Claudia
AU  - Wickenhauser C
AD  - Institute for Pathology, Martin-Luther-University Halle-Wittenberg, Halle, 
      Germany.
FAU - Seliger, Barbara
AU  - Seliger B
AD  - Institute for Medical Immunology, Martin-Luther-University Halle-Wittenberg, 
      Halle, Germany.
AD  - Department of Good Manufacturing Practice (GMP) Development & Advanced Therapy 
      Medicinal Products (ATMP) Design, Fraunhofer Institute for Cell Therapy and 
      Immunology (IZI), Leipzig, Germany.
AD  - Institute for Translational Immunology, Brandenburg Medical School (MHB), 
      Brandenburg an der Havel, Germany.
FAU - Jasinski-Bergner, Simon
AU  - Jasinski-Bergner S
AD  - Institute for Medical Immunology, Martin-Luther-University Halle-Wittenberg, 
      Halle, Germany.
AD  - Institute for Translational Immunology, Brandenburg Medical School (MHB), 
      Brandenburg an der Havel, Germany.
LA  - eng
PT  - Journal Article
DEP - 20231127
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
RN  - 0 (MicroRNAs)
RN  - 0 (Interferon Lambda)
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Humans
MH  - *MicroRNAs/genetics
MH  - Herpesvirus 4, Human/genetics/metabolism
MH  - *Epstein-Barr Virus Infections/genetics/pathology
MH  - HEK293 Cells
MH  - Interferon Lambda
MH  - *Nasopharyngeal Neoplasms/genetics/metabolism/pathology
MH  - Antiviral Agents
PMC - PMC10732682
OTO - NOTNLM
OT  - EBV
OT  - EBV target genes
OT  - IFNL3
OT  - immune escape
OT  - microRNA
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2023/12/21 06:42
MHDA- 2023/12/22 06:42
PMCR- 2023/11/27
CRDT- 2023/12/21 04:26
PHST- 2023/12/22 06:42 [medline]
PHST- 2023/12/21 06:42 [pubmed]
PHST- 2023/12/21 04:26 [entrez]
PHST- 2023/11/27 00:00 [pmc-release]
AID - 2284483 [pii]
AID - 10.1080/2162402X.2023.2284483 [doi]
PST - epublish
SO  - Oncoimmunology. 2023 Nov 27;12(1):2284483. doi: 10.1080/2162402X.2023.2284483. 
      eCollection 2023.